Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selective Neoadjuvant Treatment for HER2- Breast Cancer
NCT00432172Phase 2Completed
- Sponsor
- GEICAM
- Start
- Apr 2007
- Primary completion
- Sep 2010
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of carboplatin in breast cancer (4 arms), sponsored by GEICAM. Primary endpoint: Pathological Response for Basal Group 2 up to 24 weeks. Started Apr 2007; status: completed.
02
Drugs
carboplatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00432172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00432172.